Customers can verify COA's here: https://horizonanalytical.com/verify-coa
Supplied strictly for in-vitro and laboratory research. Not for human or veterinary use. By ordering, you confirm you are a qualified researcher handling these materials per applicable regulations and safe lab practice.
Customers can verify COA's here: https://horizonanalytical.com/verify-coa
DP3-R is a metabolic reference compound in the FastTrackLabs DP series, supplied for laboratory study of energy balance and metabolic signaling. Research interest centers on combined activity across three incretin and glucagon pathways and how that convergence affects appetite signaling, glucose handling, and energy expenditure in controlled models.
DP3-R was developed in the early 2020s as a first-in-class single-molecule triagonist acting at the GIP, GLP-1, and glucagon receptors. It entered clinical investigation for obesity and type-2-diabetes endpoints, building directly on the single- and dual-agonist classes that came before it and extending the multi-receptor design further.
DP3-R has been investigated in metabolic and endocrine models for combined GIP/GLP-1/glucagon-receptor activity affecting appetite signaling, glucose handling, and energy expenditure. The triagonist design is the defining research feature, since adding glucagon-receptor activity to the incretin pathways introduces an energy-expenditure component alongside appetite and glucose effects. As a reference triple agonist, DP3-R serves as the most complex comparator in the incretin-agonist class for laboratory metabolic research.
Manufactured in a controlled U.S. facility under strict compounding standards.
Every batch third-party tested with HPLC and mass spectrometry.
Orders dispatched same-day from our U.S. facility.
Reach out and get a response within minutes.
Everything you need to know about our products and processes.